Press Release
Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV) vaccine Eupolio™, developed by Intravacc and out-licensed to South Korean LG Chem in 2014. The…
Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification- sIPV development is part of Intravacc’s contribution to the eradication of polio
- LG Chem is the first to receive WHO prequalification for the sIPV vaccine
- LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021